Tech Company Financing Transactions

Trius Therapeutics Funding Round

Sofinnova Ventures, InterWest Partners and Prism VentureWorks participated in a $20 million Series A capital raise for Trius Therapeutics. The financing round closed on 2/27/2007.

Transaction Overview

Company Name
Announced On
2/27/2007
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series A
Investors

Sofinnova Ventures (Lead Investor) (Michael Powell)

InterWest Partners (Nina Kjellson)

Prism VentureWorks (Brendan O'Leary)

Versant Ventures (Brian Atwood)

Proceeds Purpose
The most advanced program has reached animal efficacy testing.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
6310 Nancy Ridge Drive 105
San Diego, CA 92121
USA
Email Address
Overview
Trius Therapeutics is discovering and developing innovative antibacterial drugs for thetreatment of life-threatening infections. The company's lead product candidate, TR-701 isa novel oral and IV oxazolidinone antibiotic with potent activity against Gram positivebacterial pathogens.
Profile
Trius Therapeutics LinkedIn Company Profile
Social Media
Trius Therapeutics Company Twitter Account
Company News
Trius Therapeutics News
Facebook
Trius Therapeutics on Facebook
YouTube
Trius Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Jeffrey Stein
  Jeffrey Stein LinkedIn Profile  Jeffrey Stein Twitter Account  Jeffrey Stein News  Jeffrey Stein on Facebook
Chief Financial Officer
John Schmid
  John Schmid LinkedIn Profile  John Schmid Twitter Account  John Schmid News  John Schmid on Facebook
Chief Medical Officer
Philippe Prokocimer
  Philippe Prokocimer LinkedIn Profile  Philippe Prokocimer Twitter Account  Philippe Prokocimer News  Philippe Prokocimer on Facebook
Chief Scientific Officer
John Finn
  John Finn LinkedIn Profile  John Finn Twitter Account  John Finn News  John Finn on Facebook
VP - Bus. Development
Neil Abdollahian
  Neil Abdollahian LinkedIn Profile  Neil Abdollahian Twitter Account  Neil Abdollahian News  Neil Abdollahian on Facebook
VP - Regulatory Affairs
Karen Potts
  Karen Potts LinkedIn Profile  Karen Potts Twitter Account  Karen Potts News  Karen Potts on Facebook


 

 

Browse more venture capital transactions:

Prev: 2/27/2007: Spadac venture capital transaction
Next: 2/27/2007: MATE Intelligent Video venture capital transaction

 

Share this article

 


About Our Venture Capital Transactions Database

Our team works diligently to report on tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary